HedgeChatter

  • Home /
  • Tag Archives

XLRN

Why JMP Securities Is Watching (And Loving) These 3 Biotech Stocks

In a report published Tuesday, JMP Securities named three biotech stocks it is watching: Acceleron Pharma Inc (NASDAQ: XLRN), Cardiovascular Systems Inc (NASDAQ: CSII) and Karyopharm Therapeutics Inc (NASDAQ: KPTI).Acceleron’s (Market Outperform, $52 price target) early stage clinical results at ASCO Genitourinary(GU) 2015 “support a positive outlook for maturing PFS results while providing encouragement for ongoing later stage development.”According to analyst Michael […]

February 24, 2015 , , , , , , , , , , , Comments Off on Why JMP Securities Is Watching (And Loving) These 3 Biotech Stocks read more

Acceleron to Present at 2014 UBS Global Healthcare Conference

[Business Wire] – Acceleron Pharma Inc. , a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer moreView todays social media effects on XLRNView the latest stocks trending across Twitter. Click to view dashboardSee who Acceleron is hiring next, click here to view […]

May 12, 2014 Bystocknews , Comments Off on Acceleron to Present at 2014 UBS Global Healthcare Conference read more

Acceleron Pharma to Host First Quarter 2014 Financial Results Conference Call and Webcast on May 15, 2014

[Business Wire] – Acceleron Pharma Inc. , a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer moreView todays social media effects on XLRNView the latest stocks trending across Twitter. Click to view dashboardSee who Acceleron is hiring next, click here to view […]

May 8, 2014 Bystocknews , Comments Off on Acceleron Pharma to Host First Quarter 2014 Financial Results Conference Call and Webcast on May 15, 2014 read more

4:49 pm Acceleron Pharma and Celgene (CELG) announce interim clinical data for sotatercept demonstrating dose dependent increases in hemoglobin in patients with end stage renal disease on hemodialysis

moreView todays social media effects on XLRNView the latest stocks trending across Twitter. Click to view dashboardSee who Acceleron is hiring next, click here to view […]

April 24, 2014 Bystocknews , Comments Off on 4:49 pm Acceleron Pharma and Celgene (CELG) announce interim clinical data for sotatercept demonstrating dose dependent increases in hemoglobin in patients with end stage renal disease on hemodialysis read more

3 Biggest Biotech Crashes in March

moreView todays social media effects on XLRNView the latest stocks trending across Twitter. Click to view dashboardSee who Acceleron is hiring next, click here to view […]

April 3, 2014 Bystocknews , Comments Off on 3 Biggest Biotech Crashes in March read more

7:32 am Acceleron Pharma, Celgene (CELG) and collaborators announce two publications in Nature Medicine describing sotatercept and ACE-536 therapeutic potential in beta-thalassemia and myelodysplastic syn

moreView todays social media effects on XLRNView the latest stocks trending across Twitter. Click to view dashboardSee who Acceleron is hiring next, click here to view […]

March 25, 2014 Bystocknews , Comments Off on 7:32 am Acceleron Pharma, Celgene (CELG) and collaborators announce two publications in Nature Medicine describing sotatercept and ACE-536 therapeutic potential in beta-thalassemia and myelodysplastic syn read more

4:32 pm Acceleron and Celgene (CELG) announce interim clinical data for sotatercept at 2014 National Kidney Foundation Spring Clinical Meeting; Sotatercept produces dose dependent increases in hemoglobin

moreView todays social media effects on XLRNView the latest stocks trending across Twitter. Click to view dashboardSee who Acceleron is hiring next, click here to view […]

March 18, 2014 Bystocknews , Comments Off on 4:32 pm Acceleron and Celgene (CELG) announce interim clinical data for sotatercept at 2014 National Kidney Foundation Spring Clinical Meeting; Sotatercept produces dose dependent increases in hemoglobin read more

Acceleron Pharma’s CEO Discusses Q4 2013 Results – Earnings Call Transcript

[at Seeking Alpha] – John Knopf Thanks Stephanie. Good morning everyone and thanks for joining us today. The fourth quarter of 2013 was particularly productive for Acceleron. Our three clinical candidates advanced crossed … moreView todays social media effects on XLRNView the latest stocks trending across Twitter. Click to view dashboardSee who Acceleron is hiring next, click here to view […]

March 3, 2014 Bystocknews , Comments Off on Acceleron Pharma’s CEO Discusses Q4 2013 Results – Earnings Call Transcript read more

Acceleron to Present at Cowen and Company 34th Annual Health Care Conference

[at noodls] – CAMBRIDGE, Mass.–(BUSINESS WIRE)– Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics … moreView todays social media effects on XLRNView the latest stocks trending across Twitter. Click to view dashboardSee who Acceleron is hiring next, click here to view […]

February 27, 2014 Bystocknews , Comments Off on Acceleron to Present at Cowen and Company 34th Annual Health Care Conference read more